secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001599298-26-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit FY25 GAAP net loss $1.08B, BLA accepted with PDUFA Nov 14, HARMONi-3 interim PFS Q2 2026
--------------------------------------------------------------------------------

- GAAP net loss $1,079.6M ($1.44/sh) vs $221.3M ($0.31/sh) FY24; non-GAAP net loss $347.2M ($0.46/sh).
- Cash and equivalents $713.4M at Dec 31, 2025, up from $412.3M at Dec 31, 2024.
- FDA accepted BLA for ivonescimab+chemo in EGFR-mutated NSCLC; PDUFA goal date Nov 14, 2026.
- HARMONi-3 squamous cohort screening complete; interim PFS analysis planned Q2 2026; final PFS H2 2026.
- New Phase III ILLUMINE study (GORTEC) in HNSCC to initiate; first patient expected early Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/0001599298-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000014/smmt-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer